High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients.
ASXL1
IDH
Intermediate risk cytogenetics
acute myeloid leukemia
survival
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
01
11
2021
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Prognostication of AML patients depends on association of genetic and epigenetic abnormalities. We aimed to evaluate the frequency and prognostic significance of Additional Sex comb's Like1 (ASXL1), Isocitrate Dehydrogenase (IDH) and Casitas B- lineage Lymphoma (CBL) mutations in AML assessing their association with different cytogenetic risk category. We used High Resolution Melting (HRM) technology that detects small differences in PCR amplified sequences by direct melting using EvaGreen saturating dye to analyze epigenetic mutations in 70 denovo AML patients. Median age of AML patients was 39.5 years (18-75). ASXL1, IDH and CBL mutations were detected in 14 (20%), 10 (14%) and 5 (7%) patients, respectively. Mean age of ASXL1 and IDH mutants vs. wild type was 35.9±14.6 years and 42.9±14.4 years (p=0.114) and 46.7±15.2 years vs. 40.6±14.5 years (p=0.290), respectively. AML cytogenetic risk groups included low (25/70, 36%), intermediate (33/70, 47%) and high-risk (12/70, 17%). Nine/14 (64%) ASXL1 and 8/10 (80%) IDH mutants were classified as intermediate risk and 9 ASXL1 positive (64%) were adolescent and young adults (AYA). Overall survival (OS) of mutant ASXL1 vs. wild type was 1.1 years (95% CI 0.83-1.4) vs. 1.9 years (95% CI 0.71-7.51), respectively (p=0.056). OS of mutant IDH vs. wild type was 1.25 years (95% CI 0.85-1.6) vs. 1.8 years (95% CI 1.2-6.7), respectively (p=0.020). In intermediate risk cytogenetic group, ASXL1 and IDH mutants had shorter OS than wild type; 1.1 years (95% CI 0.97-1.2) vs. 2.1 years (95% CI 0.14-10.8) (p=0.002) and 1.8 years (95% CI 0.69-3.15) vs. 2.3 years (95% CI 1.1-5.5) (p=0.05), respectively. ASXL1 and IDH mutations occur at a high incidence among young Egyptian AML patients with intermediate risk cytogenetics and confer a poorer outcome. Integration of mutations into risk profiling may predict outcome and impact therapeutic approach of young AML patient with uncertain prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Prognostication of AML patients depends on association of genetic and epigenetic abnormalities. We aimed to evaluate the frequency and prognostic significance of Additional Sex comb's Like1 (ASXL1), Isocitrate Dehydrogenase (IDH) and Casitas B- lineage Lymphoma (CBL) mutations in AML assessing their association with different cytogenetic risk category.
METHODS
METHODS
We used High Resolution Melting (HRM) technology that detects small differences in PCR amplified sequences by direct melting using EvaGreen saturating dye to analyze epigenetic mutations in 70 denovo AML patients.
RESULTS
RESULTS
Median age of AML patients was 39.5 years (18-75). ASXL1, IDH and CBL mutations were detected in 14 (20%), 10 (14%) and 5 (7%) patients, respectively. Mean age of ASXL1 and IDH mutants vs. wild type was 35.9±14.6 years and 42.9±14.4 years (p=0.114) and 46.7±15.2 years vs. 40.6±14.5 years (p=0.290), respectively. AML cytogenetic risk groups included low (25/70, 36%), intermediate (33/70, 47%) and high-risk (12/70, 17%). Nine/14 (64%) ASXL1 and 8/10 (80%) IDH mutants were classified as intermediate risk and 9 ASXL1 positive (64%) were adolescent and young adults (AYA). Overall survival (OS) of mutant ASXL1 vs. wild type was 1.1 years (95% CI 0.83-1.4) vs. 1.9 years (95% CI 0.71-7.51), respectively (p=0.056). OS of mutant IDH vs. wild type was 1.25 years (95% CI 0.85-1.6) vs. 1.8 years (95% CI 1.2-6.7), respectively (p=0.020). In intermediate risk cytogenetic group, ASXL1 and IDH mutants had shorter OS than wild type; 1.1 years (95% CI 0.97-1.2) vs. 2.1 years (95% CI 0.14-10.8) (p=0.002) and 1.8 years (95% CI 0.69-3.15) vs. 2.3 years (95% CI 1.1-5.5) (p=0.05), respectively.
CONCLUSION
CONCLUSIONS
ASXL1 and IDH mutations occur at a high incidence among young Egyptian AML patients with intermediate risk cytogenetics and confer a poorer outcome. Integration of mutations into risk profiling may predict outcome and impact therapeutic approach of young AML patient with uncertain prognosis.
Identifiants
pubmed: 35345371
doi: 10.31557/APJCP.2022.23.3.977
pmc: PMC9360955
pii:
doi:
Substances chimiques
ASXL1 protein, human
0
Repressor Proteins
0
Isocitrate Dehydrogenase
EC 1.1.1.41
IDH1 protein, human
EC 1.1.1.42.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
977-984Références
Haematologica. 2015 Feb;100(2):214-22
pubmed: 25381129
Leukemia. 2013 Jan;27(1):82-91
pubmed: 23018865
Cell Mol Life Sci. 2019 Jul;76(13):2511-2523
pubmed: 30927018
Haematologica. 2015 Mar;100(3):324-30
pubmed: 25596267
F1000Res. 2018 Aug 6;7:
pubmed: 30135719
J Blood Med. 2019 Dec 16;10:425-433
pubmed: 31908557
Int J Hematol Oncol Stem Cell Res. 2017 Oct 1;11(4):328-339
pubmed: 29340131
Cancer Cell. 2016 Aug 8;30(2):337-348
pubmed: 27424808
Pediatr Blood Cancer. 2018 Sep;65(9):e27089
pubmed: 29667722
Int J Hematol. 2016 Jun;103(6):627-33
pubmed: 26980223
J Cancer Epidemiol. 2014;2014:437971
pubmed: 25328522
Ther Adv Hematol. 2015 Jun;6(3):103-19
pubmed: 26137202
Blood Rev. 2019 Jul;36:70-87
pubmed: 31101526
Cancer Genomics Proteomics. 2016 09-10;13(5):317-29
pubmed: 27566651
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Front Oncol. 2018 Feb 23;8:41
pubmed: 29527516
Cancer. 2020 Feb 15;126(4):765-774
pubmed: 31742675
J Biol Chem. 2017 Mar 3;292(9):3666-3682
pubmed: 28082680
Leukemia. 2016 Jul;30(7):1485-92
pubmed: 27055875
Blood. 2001 Sep 1;98(5):1312-20
pubmed: 11520776
N Engl J Med. 2012 Mar 22;366(12):1079-89
pubmed: 22417203
Leuk Lymphoma. 2018 Oct;59(10):2439-2446
pubmed: 29411666
Blood. 2004 Nov 15;104(10):3078-85
pubmed: 15284114
Int J Hematol. 2018 Feb;107(2):201-210
pubmed: 29027108
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e406-e413
pubmed: 31031147
J Clin Med. 2016 Mar 05;5(3):
pubmed: 26959069
Cancer Cell. 2018 Aug 13;34(2):186-195
pubmed: 29805076
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Clin Cancer Res. 2015 Apr 15;21(8):1789-94
pubmed: 25477533
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Stem Cells Int. 2017;2017:6962379
pubmed: 28197208
Asian Pac J Cancer Prev. 2020 Mar 01;21(3):721-725
pubmed: 32212799
Leukemia. 2017 Feb;31(2):272-281
pubmed: 27721426
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Future Oncol. 2018 Apr;14(10):979-993
pubmed: 29543066
J Mol Diagn. 2012 Nov;14(6):594-601
pubmed: 22929312
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):
pubmed: 27527698
BMC Cancer. 2010 Aug 02;10:401
pubmed: 20678218